These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29423069)

  • 1. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.
    Dietrich P; Freese K; Mahli A; Thasler WE; Hellerbrand C; Bosserhoff AK
    Oncotarget; 2018 Jan; 9(3):3605-3618. PubMed ID: 29423069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of
    Zhou X; Xiao Q; Fu D; Zhang H; Tang Y; He J; Hu Y; Kong X; Teng F; Liu X; Yuan Y; Ding K
    Cancer Biol Med; 2021 Aug; 19(2):213-28. PubMed ID: 34347396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma.
    Warmington E; Smith G; Chortis V; Liang R; Lippert J; Steinhauer S; Landwehr LS; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Altieri B; Foster PA; Ronchi CL
    Endocr Connect; 2024 Jan; 13(1):. PubMed ID: 37992487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.
    Pellegrino R; Calvisi DF; Ladu S; Ehemann V; Staniscia T; Evert M; Dombrowski F; Schirmacher P; Longerich T
    Hepatology; 2010 Mar; 51(3):857-68. PubMed ID: 20112253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na).
    Monfort-Vengut A; de Cárcer G
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation.
    Bouhlal H; Ouled-Haddou H; Debuysscher V; Singh AR; Ossart C; Reignier A; Hocini H; Fouquet G; Al Baghami M; Eugenio MS; Nguyen-Khac E; Regimbeau JM; Marcq I
    Oncotarget; 2016 Mar; 7(9):9832-43. PubMed ID: 26799423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells.
    Liu W; Ning R; Chen RN; Huang XF; Dai QS; Hu JH; Wang YW; Wu LL; Xiong J; Hu G; Guo QL; Yang J; Wang H
    Mol Carcinog; 2016 May; 55(5):440-57. PubMed ID: 25683703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.
    Yoshida T; Hisamoto T; Akiba J; Koga H; Nakamura K; Tokunaga Y; Hanada S; Kumemura H; Maeyama M; Harada M; Ogata H; Yano H; Kojiro M; Ueno T; Yoshimura A; Sata M
    Oncogene; 2006 Oct; 25(45):6056-66. PubMed ID: 16652141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma.
    Fritz V; Malek L; Gaza A; Wormser L; Appel M; Kremer AE; Thasler WE; Siebler J; Neurath MF; Hellerbrand C; Bosserhoff AK; Dietrich P
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
    Wang XQ; Zhu YQ; Lui KS; Cai Q; Lu P; Poon RT
    Clin Cancer Res; 2008 Nov; 14(21):6813-20. PubMed ID: 18980975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
    Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
    Frau M; Feo F; Pascale RM
    J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma.
    Sun W; Su Q; Cao X; Shang B; Chen A; Yin H; Liu B
    Int J Genomics; 2014; 2014():312130. PubMed ID: 25019081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
    Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
    Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.